BridgeBio Pharma Files Form 4
Ticker: BBIO · Form: 4 · Filed: Apr 13, 2026
Sentiment: neutral
Topics: insider-filing, ownership-change
TL;DR
BridgeBio insiders changed their stock holdings. Keep an eye on this.
AI Summary
On April 13, 2026, BridgeBio Pharma, Inc. filed a Form 4, reporting changes in beneficial ownership of securities. The filing pertains to the period of report ending April 9, 2026. Neil Kumar is listed as a reporting person.
Why It Matters
Form 4 filings indicate changes in stock ownership by company insiders, which can signal their confidence or concerns about the company's future performance.
Risk Assessment
Risk Level: low — This is a routine filing reporting changes in beneficial ownership, not a material event like an acquisition or earnings miss.
Key Players & Entities
- BridgeBio Pharma, Inc. (company) — Issuer
- Neil Kumar (person) — Reporting Person
- 0001743881 (company) — BridgeBio Pharma CIK
- 0001742485 (person) — Neil Kumar CIK
FAQ
What type of filing is this?
This is a Form 4 filing, a Statement of changes in beneficial ownership of securities.
When was the filing accepted by the SEC?
The filing was accepted on April 13, 2026.
What is the period of report for this filing?
The period of report is April 9, 2026.
Who is listed as a reporting person?
Neil Kumar is listed as a reporting person.
What is the business address of BridgeBio Pharma, Inc.?
The business address is 3160 PORTER DR, STE 250 PALO ALTO CA 94304.
Filing Details
This Statement of Changes in Beneficial Ownership (Form 4) was filed with the SEC on April 13, 2026 by Neil Kumar regarding BridgeBio Pharma, Inc. (BBIO). Form 4 filings disclose purchases, sales, or other changes in ownership by company insiders such as officers, directors, and major shareholders.